Not for the 'Faint of Heart' | GenomeWeb

Diagnostics are a tough business, writes life sciences venture capitalist Bruce Booth.

And he should know — he's currently in the process of unwinding cancer diagnostics company On-Q-Ity, an investment by his firm, Atlas Ventures, that didn't quite work out.

The reading public is the beneficiary of Booth's loss, though, as he performs a post-mortem of sorts, looking at what went wrong.

Among the lessons learned:

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Change Afoot

Words to Dollars

To Regulate or Not?

This Week in PLOS

Best Candidates

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?